Advances in Chronic Kidney Disease
Volume 14, Issue 2 , Pages 178-190, April 2007

Hypertension in Pregnancy

  • Tiina Podymow

      Affiliations

    • Division of Nephrology, McGill University Health Center, Monteal, Quebec, Canada
    • Corresponding Author InformationAddress correspondence to Tiina Podymow, MD, Division of Nephrology, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
  • ,
  • Phyllis August

      Affiliations

    • Division of Nephrology and Hypertension, Weill Medical College of Cornell University, New York, NY.

Hypertensive disorders of pregnancy are the most common medical disorders of pregnancy and are associated with increased maternal and perinatal risks. The pathophysiology, diagnosis, and treatment are herein reviewed for chronic hypertension, preeclampsia, gestational hypertension, and severe hypertension. The benefits and risks of treating mild, moderate, and severe hypertension are discussed. A variety of oral and parenteral therapies are approved for the treatment of hypertension in pregnancy; methyldopa, labetalol, and nifedipine have been used safely in pregnancy, as has hydrochlorothiazide in those already taking this medication before conception. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are contraindicated in pregnancy because of adverse fetal effects, and atenolol should be avoided due to concerns with fetal growth. Severe hypertension >160/110 mmHg may require parenteral therapy, and treatment with intravenous labetalol now supplants the use of hydralazine. Women may remain hypertensive for a period postpartum and require treatment for a short interval. Early or severe preeclampsia warrants workup postpartum for secondary causes. Pregnancy induced hypertension or preeclampsia are emerging as risk factors for future cardiovascular risk.

Index Words: Hypertension, pregnancy, preeclampsia, antihypertensive, blood pressure

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1548-5595(07)00009-2

doi:10.1053/j.ackd.2007.01.008

Advances in Chronic Kidney Disease
Volume 14, Issue 2 , Pages 178-190, April 2007